Evaluation of long-term efficacy, safety, and reasons for discontinuation of dupilumab for moderate to severe atopic dermatitis in clinical practice: A retrospective cohort study
- 16 February 2020
- journal article
- letter
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 82 (6), 1530-1532
- https://doi.org/10.1016/j.jaad.2020.02.029
Abstract
No abstract availableFunding Information
- Sanofi
- Regeneron
- Sanofi
- AbbVie
- Cardiff University
- AbbVie
- Almirall
- Alliance
- Beiersdorf UK Ltd
- BIOTEST
- Celgene
- Dermal
- Eli Lilly
- Galderma
- Genus Pharma
- GlobeMicro
- Janssen-Cilag
- LaRoche-Posay
- L'Oréal
- LEO Pharma
- Meda
- Merck Sharp & Dohme
- Novartis
- Pfizer
- Sinclair Pharma
- Spirit
- Stiefel
- Samumed
- Thornton Ross
- TyPharm
- UCB
- Sanofi
This publication has 4 references indexed in Scilit:
- Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic DermatitisJAMA Dermatology, 2020
- Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric seriesDermatologic Therapy, 2019
- Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trialsBritish Journal of Dermatology, 2019
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017